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Abstract
Persistence of high-risk (HR-) human papillomavirus (HPV) infection of the uterine cervix increases the risk of cervical cancer. Oral HPV
infections are among potential covariates of long-term genotype-speciﬁc persistent cervical HR-HPV infections. It is not known whether this
persistence reﬂects inability of the host to reject HPV infections in general. A case–control setting was designed to estimate the covariates
of long-term persistent cervical HR-HPV infections using multivariate generalized estimating equation (GEE) models. HPV was detected with
PCR using GP05+/GP06+-primers and genotyped for 24 HPVs with a Multimetrix-kit. The cases (n = 43) included women who had
genotype-speciﬁc persistent cervical HR-HPV infection for at least 24 months (24M+) and controls were women who tested repeatedly
HPV-negative in their cervical samples (n = 52). These women represent a sub-cohort of the Finnish Family HPV Study. The cases differed
signiﬁcantly from the HPV-negative controls in several aspects: they were younger, had a longer mean time to incident oral HPV infection
(40.7 versus 23.6 months), longer duration of oral HPV persistence (38.4 versus 14.1 months), and longer time to clearance of their oral
HPV infection (50.0 versus 28.2 months). In multivariate GEE analysis, the second pregnancy during the follow up was the only independent
predictor with signiﬁcant protective effect against 24M+ persistent cervical HR-HPV infections, OR of 0.15 (95% CI 0.07–0.34). To
conclude, long-term persistent cervical HR-HPV infections are associated with a prolonged clearance of oral HR-HPV infections while new
pregnancy protects against persistent cervical HR-HPV infections.
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Introduction
Persistent high-risk (HR) human papillomavirus (HPV) infection
is necessary for the development of cervical cancer and its
precursors [1]. Persistent HPV infections lasting >12 months
(12M+) appear to be associated with an increased risk for
disease progression [1–3]. Most recent data also imply that the
strength of HPV persistence as a predictor of progressive
disease varies substantially. It is critically dependent on the
reference category used in these assessments, the consistently
HPV-negative status as the reference group providing the
highest relative risks (RRs) [2]. There is also no generally
accepted deﬁnition of HPV persistence [1,4]. The most
commonly used deﬁnition is two or more HPV DNA-positive
tests during the follow up [1,5]. Other studies have evaluated
persistence based on time to virus clearance or by counting
the proportion of HPV-positive visits [6–8]. Consecutive
HPV-positivity has been the requirement in most of these
studies, but some have also accepted intervening HPV-negative
visits as the criteria of persistent HPV [6,8].
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Known risk factors for persistent genital HPV infections
include older age, smoking, long-term use of oral contracep-
tives, high parity, number of sexual partners and exposure to
other sexually transmitted diseases [9–11]. Currently, the
evidence is considered sufﬁcient to conﬁrm the causal
association of HPV infection also with oropharyngeal and oral
cancers [12]. Most studies on HPV in the head and neck region
have focused on HPV prevalence in cancers, whereas the
natural history of asymptomatic oral HPV infections is
incompletely understood [12,13]. In this study, oral HPV
infections are studied among potential covariates of long-term
(i.e. 24M+), genotype-speciﬁc persistent cervical HR-HPV
infections in a case–control setting, with consistently
HPV-negative women as the reference group.
Materials and Methods
Subjects
The Finnish Family HPV study (FFHPV) is a prospective cohort
study designed to investigate the natural history of oral and
genital HPV infections among the members of regular families
[4,14]. The study is jointly conducted by the Institute of
Dentistry, Faculty of Medicine, University of Turku, and the
Department of Obstetrics and Gynaecology, Turku University
Hospital (TUH). Altogether, 329 mothers-to-be (mean age
25.5 years) were enrolled at the minimum of 36 weeks of
gestation of their index pregnancy and followed-up for 6 years
(mean time 54.9 months) after delivery. In the present study, a
case–control setting was used to estimate the covariates of
long-term persistence of cervical HR-HPV infections. The
cases (n = 43) included women who had genotype-speciﬁc
persistent cervical HR-HPV infection for at least 24 months
(24M+) and the controls were women who tested constantly
HPV-negative in their repeated cervical samples (n = 52). A
structured questionnaire for recording demographic data and
potential risk factors was recorded at baseline and 6-year
follow-up visits. The Joint Commission on Ethics of Turku
University and TUH has approved the study protocol and its
amendments (#2/1998 and #2/2006).
Cervical and oral scrapings for HPV genotyping
Cervical and oral scrapings were taken for HPV testing with a
cytobrush (Cytobrush, MedScand, Malm€o, Sweden) as
described earlier [4,14,15]. HPV was detected with PCR using
GP05+/GP06+-primers [16]. PCR product was hybridized with
a digoxigenin-labelled HR-HPV–oligoprobe cocktail containing
12 HR-HPV oligoprobes [17]. The existing PCR products were
biotinylated by re-ampliﬁcation with GP05+ and bio-GP06+
primers for HPV genotyping by Luminex-based Multimetrix kit
(Progen Biotechnik GmbH, Heidelberg, Germany), which
detects 24 low-risk (LR-) and HR-HPV genotypes (LR-HPV:
6, 11, 42, 43, 44, 70; HR-HPV: 16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73, 82) [18].
Blood samples for HPV serology
Blood samples for analysis of HPV antibodies were taken at
baseline and at 12, 24 and 36 months of follow up. Antibodies
to the major capsid protein L1 of HPV types 6, 11, 16, 18 and
45 were analysed in the German Cancer Research Centre
(Heidelberg), with Multiplex HPV serology [19]. The cut-off
value of 200 median ﬂuorescence intensity was used [20].
Statistical analyses
To analyse the potential covariates of long-term (24M+)
genotype-speciﬁc persistent cervical HR-HPV infections in a
case–control setting, a sub-cohort of FFHPV study was built
up: (i) the case group which included 43 mothers who had a
genotype-speciﬁc persistent cervical HR-HPV infection of at
least 24M+ duration, and (ii) the control group comprising 52
mothers who tested HPV-negative in their cervical samples
throughout the follow-up period. Key epidemiological charac-
teristics were compared between these two groups. Oral HPV
persistence was deﬁned as two or more consecutive oral
HPV-positive visits during the follow up. Frequency tables
were analysed using the v2-test, with the likelihood ratio or
Fisher’s exact test for categorical variables. Differences in
the means of continuous variables were analysed using
non-parametric (Mann–Whitney or Kruskal–Wallis) tests for
two and multiple independent samples, respectively.
Generalized estimating equation (GEE) modelling was used
to analyse the predictors of long-term persistence of cervical
HR-HPV infections. In univariate GEE models, we ﬁrst tested
all the covariates recorded at baseline (including serological
data) and previously implicated as potential risk factors of HPV
infections in this cohort [4,14]. In the ﬁnal multivariate GEE
model, only the variables that were statistically signiﬁcant in
the univariate model were entered, adjusted for age (contin-
uous variable). All statistical analyses were run using SPSS
(IBM Corp., Armonk, NY, USA) and STATA (Stata Corp.,
College Station, TX, USA) software packages (PASW Statistics
for Windows 19.0.1 and STATA/SE 12.0).
Results
The key characteristics of the cases and the controls are
shown in Table 1. The mean follow-up time for the cases was
65.2 months (95% CI 58.5–71.9) and that of the controls was
38.4 months (95% CI 30.2–46.7). Among the 43 cases, the
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following HPV genotypes were recorded to persist in the
cervix for 24M+: HPV16 (n = 36), HPV35 (n = 1), HPV45
(n = 1), HPV52 (n = 2) and multiple HPV types (n = 3) (data
not shown). The mean time of cervical HPV persistence was
36.0 months (95% CI 24.1–78.8). The cases were younger
(mean age 25.2 versus 26.4 years), had longer (mean) time to
incident oral HPV infections (40.7 versus 23.6 months), longer
duration of persistent oral HPV infections (30.6 versus
11.7 months), and the clearance of their oral HPV infections
was more prolonged (50.0 versus 28.2 months).
The persistent oral HPV infections among the cases
included the following HPV types: HPV16 (n = 13) and
multiple HPV types (n = 5). Type-speciﬁc concordance
between the persisting cervical and oral HPV (n = 13) was
not signiﬁcant. However, as to the overall HPV persistence by
follow-up visit, oral and cervical HPV persistence were
signiﬁcantly correlated (Likelihood ratio, 11.8; p 0.001).
Women with a persistent cervical HPV infection had an
increased risk of having a co-incident persistent oral
HPV infection at the same visit, with OR of 3.31 (95% CI
1.71–6.39).
As to the dynamics of genotype-speciﬁc HPV serology (for
HPV6, 11, 16, 18 and 45) in the cases and the controls, no
differences were disclosed in HPV antibody titres at any of the
follow-up visits. The same was true with the rates and times of
type-speciﬁc sero-conversion. However, the cases were more
TABLE 1. Key epidemiological characteristics of the cases and controls
Characteristics
Cases
persistent cervical HPV
infection (n = 43)
Controls
constantly HPV-negative in cervical
samples (n = 52) p value*
Mean age (years, 95% CI) 25.2 (24.4–25.9) 26.4 (25.4–27.3) 0.054
Not married (single) 2.4% (1/42) 0% (0/51) 0.268
Employment
Employed 59.5% (25/42) 70.6% (36/51) 0.534
Student 16.7% (7/42) 11.8% (6/51)
Unemployed 23.8% (10/42) 17.6% (9/51)
Age at ﬁrst intercourse
≤13 years 2.4% (1/42) 2.0% (1/51) 0.938
14–16 years 57.1% (24/42) 51.0% (26/51)
17–19 year 35.7% (15/42) 41.2% (21/51)
>20 years 4.8% (2/42) 5.9% (3/51)
Number of sex partners before age 20 years
0–2 partners 50.0% (21/42) 43.1% (22/51) 0.869
3–5 partners 26.2% (11/42) 29.4% (15/51)
6–10 partners 14.3% (6/42) 19.6% (10/51)
>10 partners 9.5% (4/42) 7.8% (4/51)
Number of lifetime sex partners
0–2 35.7% (15/42) 21.6% (11/51) 0.449
3–5 21.4% (9/42) 29.4% (15/51)
6–10 28.6% (12/42) 29.4% (15/51)
>10 14.3% (6/42) 19.6% (10/51)
Number of intercourses/month
0–1 2.4% (1/42) 2.0%1/51) 0.190
2–4 35.7% (15/42) 19.6% (10/51)
5–10 52.4% (22/42) 60.8% (31/51)
>10 7.1% (3/42) 17.6% (9/51)
Having oral sex (yes) 83.3% (35/42) 76.5% (39/51) 0.451
Having anal sex (yes) 23.8% (10/42) 15.7% (8/51) 0.430
Age at starting oral contraception
Never 9.5% (4/42) 6.0% (3/50) 0.616
14–16 years 31.0% (13/42) 44.0% (22/50)
17–19 years 45.2% (19/42) 38.0% (19/50)
>20 years 14.3% (6/42) 12.0% (6/50)
Use of oral contraception (yes) 90.5% (38/42) 94.0% (47/50) 0.698
Ever been smoker 48.8% (20/41) 56.0% (28/50) 0.532
Age of initiating smoking
10–13 years 10.5% (2/19) 20.0% (4/20) 0.931
14–17 years 73.7% (14/19) 65.0% (13/20)
18–21 years 10.5% (2/19) 10.0% (2/20)
22–25 years 5.3% (1/19) 5.0% (1/20)
Ever had a sexually transmitted disease 76.7% (33/43) 73.1% (38/52) 0.813
Never had genital warts 66.7% (28/42) 64.0% (32/50) 0.829
Never had oral papillomas 92.7%(38/41) 95.9% (47/49) 0.656
Seropositive to HPV 16, 18, 45 (Baseline) 42.9% (18/42) 26.9% (14/52) 0.128
Seropositive to HPV 6 or 11 (Baseline) 50.0% (21/42) 65.4% (34/52) 0.146
Oral HR-HPV positive (Baseline) 14.0% (6/43) 13.5% (7/52) 1.000
Seroconversion to HPV 16, 18, or 45 27.9% (12/43) 21.2% (11/52) 0.479
Seroconversion to HPV 6 or 11 25.6% (11/43) 25.0% (13/52) 1.000
Pap smear ≥ASCUS 16.7% (7/42) 15.4% (8/52) 1.000
Persistent oral HPV 30.2% (13/43) 21.6% (11/51) 0.354
Mean time to incident oral HPV infection (Oral baseline negative) (months) 40.7 (30.8-50.6) 23.6 (16.5-30.6) 0.005
Mean time of oral persistent HPV infection (months) 30.6 (15.6-45.6) (n = 13) 11.7 (7.6-15.9) (n = 11) 0.023
Mean time to oral HPV clearance (all at risk) (months) 50.0 (36.4-63.6) (n = 24) 28.2 (18.4-38.0) (n = 28) 0.009
*Signiﬁcant associations are highlighted in bold (p ≤0.05), Signiﬁcance between Cases and Controls; analysis of variance test for all continuous variables; Fisher’s exact test for all
comparisons where any cell in the contingency table contains fewer than ﬁve observations.
ASCUS, atypical squamous cells of undetermined signiﬁcance; HR-HPV, high-risk human papillomavirus.
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likely to be HPV16-seropositive at the baseline visit than the
controls (40.5% versus 19.2%; OR 2.1, 95% CI 1.08–4.10).
Table 2 shows the covariates associated with 24M+ persis-
tence of cervical HR-HPV infections. In the univariate GEE
model, three signiﬁcant predictors were found: (i) age; the risk
was reduced with age, OR of 0.90 (95% CI 0.82–0.99), (ii)
second pregnancy during the follow up; women with a second
pregnancy were protected (OR 0.16, 95% CI 0.08–0.31); and
(iii) having a new partner during the follow up, increasing the
risk (OR 1.90, 95% CI 1.01–3.58). After adjustment for age in
the multivariate GEE model, only the second pregnancy
retained its signiﬁcance as an independent predictor of 24M+
persistence. Women who had a second pregnancy during the
follow up were signiﬁcantly protected against persistent
HR-HPV infection (OR 0.15, 95% CI 0.07–0.34).
Discussion
According to our knowledge, this is one of the ﬁrst studies to
demonstrate in a longitudinal setting that long-term persis-
tence of cervical HR-HPV infections might affect the outcome
of HPV infections at other mucosal sites, i.e. oral mucosa in
this case. Our data implicate that women with persistent
cervical HPV infections of 24M+, acquired an incident oral HPV
infection later (40.7 versus 23.6 months), their oral HR-HPV
infections persisted nearly three times longer than in (cervical)
HPV-negative controls (30.6 versus 11.7 months), and also
cleared more slowly than among women with no cervical HPV
infection (50.0 versus 28.2 months). Also the risk for devel-
oping a persistent oral infection was over three-fold higher
among the cases than in the controls (OR 3.31).
Recent cross-sectional studies have shown that the prev-
alence of oral HPV infections is higher among women with
concurrent cervical HPV infection [13,21]. One of these
studies also reported a moderate type-speciﬁc HPV concor-
dance between the oral and genital HPV types [21]. We could
not record any signiﬁcant concordance between the persistent
cervical and oral HPV genotypes, which is most likely because
of the limited number of such cases and possibly because of the
longitudinal setting of the present study. It has been speculated
that subjects with a concomitant cervical and oral HPV
infection might represent a subgroup of women with an
increased inherent susceptibility to HPV infection, possibly due
to an impaired immune response [13]. Our serological data
from the present case–control setting showed that women in
the case group were more likely to be HPV16-seropositive at
their baseline visit. They also had lower titres of HPV16
antibodies at all follow-up visits compared with the women in
the HPV-negative control group. Although these differences
did not reach statistical signiﬁcance, these data might indicate a
tendency towards compromised antibody response among the
Covariates
Univariate GEE
model
Multivariate GEE
model
OR 95% CI ORc 95% CI
Age 0.90 0.82–0.99 0.89 0.78–1.01
Mother seroconverted to HR-HPV (yes; ref.) 0.73 0.37–1.44
Mother seropositive to HR-HPV at baseline (yes; ref.) 1.01 0.56–1.80
Baseline oral HR-HPV DNA status (neg; ref.) 1.23 0.70–2.17
Baseline PAP smear (<ASCUS; ref.) 0.57 0.21–1.52
Living with partner at baseline (single; ref.) 0.86 0.13–5.67
Employment status (employed; ref.) 1.15 0.81–1.63
Age at onset of sexual activity (<13 years; ref.) 0.78 0.47–1.31
No. of sexual partners until age 20 years (0–2; ref.) 1.07 0.77–1.49
Life-time number of sexual partners (0–2; ref.) 0.94 0.70–1.25
No of weekly intercourse (0–1; ref.) 0.77 0.51–1.17
No of deliveries in all partnerships (1; ref.) 0.52 0.23–1.17
Practices of oral sex (no; ref.) 1.45 0.64–3.29
Practices of anal sex (no; ref.) 1.52 0.75–3.09
Initiation of OC usage (<13 years; ref.) 1.21 0.79–1.86
OC use (Y/N) (never use; ref.) 0.62 0.21–1.78
Smoking habits (never; ref.) 1.22 0.66–2.27
Initiation of smoking (10–13 years; ref.) 1.05 0.55–1.99
History of sexually transmitted disease (no; ref. 0.96 0.47–1.98
History of genital warts (yes; ref) 1.02 0.53–1.96
History of oral warts (no history; ref.) 1.28 0.44–3.75
Second pregnancy during follow up (no; ref.) 0.16 0.08–0.31 0.15 0.07–0.34
Change in marital status during follow up (no; ref.) 1.05 0.84–1.31
New partner during follow up (no; ref.) 1.90 1.01–3.58 1.49 0.86–3.26
No of current sexual partners (0; ref.) 0.70 0.26–1.89
aBinary outcome (persistent/not persistent), as deﬁned by persistence at least 24M+ during the follow up.
bResults obtained from GEE with logit link for binary outcomes, clustered by woman’s ID, 95% CI calculated by robust
variance estimation.
cAdjusted for age and all signiﬁcant univariates in the model; signiﬁcant results are shown in bold type.
ASCUS, atypical squamous cells of undetermined signiﬁcance; GEE, generalized estimating equation; HR-HPV, high-risk
human papillomavirus; OC, oral contraceptive.
TABLE 2. Covariates of long term
(24M+ months) persistenta cervical
high-risk human papillomavirus
infections in univariate and multivar-
iate generalized estimating equation
modelsb
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cases and their failure to clear chronic cervical HPV infections,
particularly those caused by the HPV16 genotype. Our
previous ﬁndings in the whole FFHPV (women) cohort
disclosed no correlations between oral HPV DNA detection
and HPV serology [22]. Interestingly, however, the data did
show the highest titres of HPV type-speciﬁc antibodies among
women who cleared their cervical HPV16 infection, whereas
the women who acquired incident cervical HPV16 infections
had the lowest HPV16 antibody levels [22].
In the present study, women with 24M+ HPV-persistence
were 1 year younger than the HPV-negative controls (25.2
versus 26.4 years). Consequently, in the GEE model, the risk of
persistence declined signiﬁcantly with age. Because all the
women in the FFHPV study comprise a rather homogeneous
cohort, i.e. all were young mothers-to-be at enrolment [14],
these data indicate that there may be a subgroup of women in
whom HPV persistence is established at a young age and not
later, as suggested by some previous studies [9–11]. Only one
recent study showed that younger age can be a risk factor for
persistent HPV infections [23]. Interestingly, our recent results
showed that children who were born to the mothers with
incident cervical intraepithelial neoplasia lesions already had
HPV16-speciﬁc cell-mediated immunity [24]. All of these
children were sexually naive and were not vaccinated against
HPV. Accordingly, HPV infections at an early agemight affect the
outcome of genital or oral HPV infections later in life. The
present observations ﬁt with the dynamicmodel of cervical HPV
infections, peaking at around 24 years of age, with steadily
declining age-speciﬁc HPV prevalence until menopause [3,25].
In estimating the covariates of 24M+ persistent cervical
HR-HPV infections, only the second pregnancy during the
follow up remained signiﬁcant in the adjusted GEE model. This
is in line with our previous results from the whole FFHPV
cohort, showing that the second pregnancy was a potent
protective factor against incident cervical HPV infections [26].
Similarly, we have demonstrated that the risk for incident oral
HPV infections and their persistence is markedly decreased by
a new pregnancy [15,27]. Most previous studies have focused
only on differences in HPV prevalence among the pregnancy
trimesters [28,29]. A recent study showed that among
persistent HPV infections, childbirth proved to be a cofactor
for high-grade cervical disease but not pregnancy [30]. HPV
and pregnancy is still a controversial issue, and the mechanistic
explanation for this observed protective effect in our study
must be complex. We have previously found that women
committed to the second child in our FFHPV cohort did not
have most of the known life-style behavioural risk factors of
HPV infection [31]. In addition to these obvious differences in
the behavioural pattern between the women with and without
a second pregnancy, we cannot ignore the effects of
pregnancy-associated hormonal changes as potential speciﬁc
modulators of the host response to HPV.
The strength of the present study is the case–control
setting; the cases comprise women with long-term persistent
cervical HR-HPV infections, and the controls consist of women
who remained completely HPV-negative throughout their
follow up. Noteworthy, our deﬁnition of HPV persistence was
exceptionally stringent compared with many previous studies,
because a minimum of 24 months of persistence was required,
recorded at consequent follow-up visits [1,2]. Furthermore,
our study is the ﬁrst to correlate oral and cervical HPV
infections in a longitudinal setting, in contrast to the previous
cross-sectional studies [13,21].
Taken together, these results strongly suggest that long--
term cervical HR-HPV persistence might be an indicator of a
compromised host response to co-existent oral HPV infec-
tions as well. Becoming pregnant during the follow up seems to
confer a signiﬁcant protective effect against long-term persis-
tence of cervical HR-HPV.
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